GSK nears end of OTC bidding process

GlaxoSmithKline ($GSK) is weighing final offers for the portfolio of over-the-counter products it has put on the block, sources tell Reuters. The two front-runners in the second round of bidding are Bain Capital and a partnership between Blackstone and Prestige Brands, the sources said. Report

Suggested Articles

Saturday, AstraZeneca revealed more of the data that convinced the FDA to green-light Calquence in previously untreated chronic lymphocytic leukemia.

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.